Study endpoints
| Endpoint | Time point |
| Efficacy: primary | |
| Annual rate of decline in FVC | Over 52 weeks |
| Efficacy: main secondary | |
| K-BILD total score | Change from baseline to week 52 |
| Time to first acute ILD exacerbation or death | Over 52 weeks |
| Time to death | Over 52 weeks |
| Efficacy: other secondary | |
| Time to death due to respiratory cause | Over 52 weeks |
| Time to progression (≥10% absolute decline in FVC % predicted) or death | Over 52 weeks |
| Proportion of patients with a relative decline in FVC % predicted of >10% | Baseline to week 52 |
| Proportion of patients with a relative decline in FVC % predicted of >5% | Baseline to week 52 |
| L-PF symptoms, dyspnoea domain score | Change from baseline to week 52 |
| L-PF symptoms, cough domain score | Change from baseline to week 52 |
| Safety | |
| AEs | Over 52 weeks* |
| Physical examination | |
| Vital signs | |
| Body weight | |
Clinical laboratory tests.
*Primary safety assessment—selected safety analyses will be repeated to include data collected beyond 52 weeks (part B of the study).
AE, adverse event; FVC, forced vital capacity; ILD, interstitial lung disease; K-BILD; King’s Brief Interstitial Lung Disease Questionnaire; L-PF, living with pulmonary fibrosis.